Moderate to Severe Osteoarthritis Pain and Its Impact on Patients in the United States: A National Survey

References

• Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012;13(8):715–724. doi:10.1016/j.jpain.2012.03.009
   PubMed Web of Science ®Google Scholar
• Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an internet-based survey. J Pain. 2010;11(11):1230–1239. doi:10.1016/j.jpain.2010.07.002
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation–United States, 2010–2012. MMWR Morb Mortal Wkly Rep. 2013;62(44):869–873.
   PubMed Web of Science ®Google Scholar
• United States Bone and Joint Initiative. Osteoarthritis. The Burden of Musculoskeletal Diseases in the United States (BMUS). Rosemont, IL; 2018: Available from: https://www.boneandjointburden.org/fourth-edition. Accessed January 14, 2020.
   Google Scholar
• Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage. 2013;21(9):1145–1153. doi:10.1016/j.joca.2013.03.018
   PubMed Web of Science ®Google Scholar
• Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis. Br Med Bull. 2013;105:185–199. doi:10.1093/bmb/lds038
   PubMed Web of Science ®Google Scholar
• Deshpande BR, Katz JN, Solomon DH, et al. Number of persons with symptomatic knee osteoarthritis in the US: impact of race and ethnicity, age, sex, and obesity. Arthritis Care Res (Hoboken). 2016;68(12):1743–1750. doi:10.1002/acr.22897
   PubMed Web of Science ®Google Scholar
• Osteoarthritis Research Society International (OARSI). Osteoarthritis: a serious disease, submitted to the U.S. Food and Drug Administration; 2016. Available from: https://oarsi.org/sites/default/files/docs/2016/oarsi_white_paper_oa_serious_disease_121416_1.pdf. Accessed January 14, 2021.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Osteoarthritis (OA); 2020. Available from: https://www.cdc.gov/arthritis/basics/osteoarthritis.htm. Accessed January 14, 2021.
   Google Scholar
• Bitton R. The economic burden of osteoarthritis. Am J Manag Care. 2009;15(8 Suppl):S230–235.
   PubMedGoogle Scholar
• Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA. Osteoarthritis and absenteeism costs: evidence from US National Survey Data. J Occup Environ Med. 2010;52(3):263–268. doi:10.1097/JOM.0b013e3181cf00aa
   PubMed Web of Science ®Google Scholar
• Gore M, Tai KS, Sadosky A, Leslie D, Stacey BR. Clinical comorbidities, treatment patterns, and healthcare costs of patients with osteoarthritis in usual care: a database analysis. J Med Econ. 2011;14(4):497–507. doi:10.3111/13696998.2011.594347
   PubMedGoogle Scholar
• Berger A, Bozic K, Stacey B, Edelsberg J, Sadosky A, Oster G. Patterns of pharmacotherapy and health care utilization and costs prior to total hip or total knee replacement in patients with osteoarthritis. Arthritis Rheum. 2011;63(8):2268–2275. doi:10.1002/art.30417
   PubMed Web of Science ®Google Scholar
• DiBonaventura M, Gupta S, McDonald M, Sadosky A. Evaluating the health and economic impact of osteoarthritis pain in the workforce: results from the National Health and Wellness Survey. BMC Musculoskelet Disord. 2011;12:83. doi:10.1186/1471-2474-12-83
   PubMed Web of Science ®Google Scholar
• Gore M, Tai KS, Sadosky A, Leslie D, Stacey BR. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings. Pain Pract. 2012;12(7):550–560. doi:10.1111/j.1533-2500.2012.00532.x
   PubMed Web of Science ®Google Scholar
• Murphy L, Helmick CG. The impact of osteoarthritis in the United States: a population-health perspective. Am J Nurs. 2012;112(3 Suppl 1):S13–19. doi:10.1097/01.NAJ.0000412646.80054.21
   PubMed Web of Science ®Google Scholar
• Xie F, Kovic B, Jin X, He X, Wang M, Silvestre C. Economic and humanistic burden of osteoarthritis: a systematic review of large sample studies. Pharmacoeconomics. 2016;34(11):1087–1100. doi:10.1007/s40273-016-0424-x
   PubMed Web of Science ®Google Scholar
• Wang SX, Ganguli AX, Bodhani A, Medema JK, Reichmann WM, Macaulay D. Healthcare resource utilization and costs by age and joint location among osteoarthritis patients in a privately insured population. J Med Econ. 2017;20(12):1299–1306. doi:10.1080/13696998.2017.1377717
   PubMed Web of Science ®Google Scholar
• Zhao X, Shah D, Gandhi K, et al. Clinical, humanistic, and economic burden of osteoarthritis among noninstitutionalized adults in the United States. Osteoarthritis Cartilage. 2019;27(11):1618–1626. doi:10.1016/j.joca.2019.07.002
   PubMed Web of Science ®Google Scholar
• Sadosky A, Bushmakin A, Cappelleri JC, Lionberger DR. Relationship between patient-reported disease severity in osteoarthritis and self-reported pain, function, and work productivity. Arthritis Res Ther. 2010;12:R162. doi:10.1186/ar3121
   PubMed Web of Science ®Google Scholar
• DiBonaventura M, Gupta S, McDonald M, Sadosky A, Pettit D, Silverman S. Impact of self-rated osteoarthritis severity in an employed population: cross-sectional analysis of data from the national health and wellness survey. Health Qual Life Outcomes. 2012;10:30. doi:10.1186/1477-7525-10-30
   PubMed Web of Science ®Google Scholar
• Wei W, Gandhi K, Blauer-Peterson C, Johnson J. Impact of pain severity and opioid use on health care resource utilization and costs among patients with knee and hip osteoarthritis. J Manag Care Spec Pharm. 2019;25(9):957–965. doi:10.18553/jmcp.2019.25.9.957
   PubMed Web of Science ®Google Scholar
• Jackson J, Iyer R, Mellor J, Wei W. The burden of pain associated with osteoarthritis in the hip or knee from the patient’s perspective: a multinational cross-sectional study. Adv Ther. 2020;37(9):3985–3999. doi:10.1007/s12325-020-01445-4
   PubMed Web of Science ®Google Scholar
• Nalamachu SR, Robinson RL, Viktrup L, et al. Multimodal treatment patterns for osteoarthritis and their relationship to patient-reported pain severity: a cross-sectional survey in the United States. J Pain Res. 2020;13:3415–3425. doi:10.2147/JPR.S285124
   PubMed Web of Science ®Google Scholar
• Nalamachu S, Robinson RL, Viktrup L, et al. Pain severity and healthcare resource utilization in patients with osteoarthritis in the United States. Postgrad Med. 2021;133(1):10–19. doi:10.1080/00325481.2020.1841988
   PubMed Web of Science ®Google Scholar
• Bellamy N. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC); 2021. Available from: http://www.auscan.org/womac/index.htm. Accessed January 14, 2021.
   Google Scholar
• Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1(3):277–299. doi:10.1016/0304-3959(75)90044-5
   PubMed Web of Science ®Google Scholar
• Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191–197. doi:10.1016/0304-3959(87)91074-8
   PubMed Web of Science ®Google Scholar
• Ware JE, Kosinski M, Turner-Bowker D, Sundaram M, Gandek B, Maruish ME. User’s Manual for the SF-12v2 Health Survey Second Edition. Lincoln, RI: QualityMetric Incorporated; 2009.
   Google Scholar
• Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S240–252.
   PubMed Web of Science ®Google Scholar
• Kantar Health. National Health and Wellness Survey. Patient-reported healthcare insights; 2019. Available from: https://www.kantarhealth.com/docs/datasheets/kh-national-health-and-wellness-survey.pdf. Accessed January 28, 2021.
   Google Scholar
• Boonstra AM, Schiphorst Preuper HR, Balk GA, Stewart RE. Cut-off points for mild, moderate, and severe pain on the visual analogue scale for pain in patients with chronic musculoskeletal pain. Pain. 2014;155(12):2545–2550. doi:10.1016/j.pain.2014.09.014
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Maruish M, Maruish M, Kosinski M, et al. User’s Manual for the SF36v2 Health Survey. 3rd Ed. Lincoln, RI: QualityMetric Incorporated; 2011.
   Google Scholar
• Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–292. doi:10.1016/S0167-6296(01)00130-8
   PubMed Web of Science ®Google Scholar
• The EuroQol Group. EQ-5D-5L user guide; 2021. Available from: https://euroqol.org/publications/user-guides/. Accessed June 11, 2017.
   Google Scholar
• Conner-Spady BL, Marshall DA, Bohm E, et al. Reliability and validity of the EQ-5D-5L compared to the EQ-5D-3L in patients with osteoarthritis referred for hip and knee replacement. Qual Life Res. 2015;24(7):1775–1784. doi:10.1007/s11136-014-0910-6
   PubMed Web of Science ®Google Scholar
• Bilbao A, Garcia-Perez L, Arenaza JC, et al. Psychometric properties of the EQ-5D-5L in patients with hip or knee osteoarthritis: reliability, validity and responsiveness. Qual Life Res. 2018;27(11):2897–2908. doi:10.1007/s11136-018-1929-x
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353–365. doi:10.2165/00019053-199304050-00006
   PubMed Web of Science ®Google Scholar
• Reilly MC. Work productivity and activity impairment questionnaire: specific health problem V2.0 (WPAI:SHP); 2010. Available from: http://www.reillyassociates.net/WPAI_SHP.html. Accessed January 14, 2021.
   Google Scholar
• Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000;42(3):241–247. doi:10.1016/S0920-9964(99)00130-9
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain–United States, 2016. JAMA. 2016;315(15):1624–1645. doi:10.1001/jama.2016.1464
   PubMed Web of Science ®Google Scholar
• Dakin P, DiMartino SJ, Gao H, et al. The efficacy, tolerability, and joint safety of fasinumab in osteoarthritis pain: a phase IIb/III double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol. 2019;71(11):1824–1834. doi:10.1002/art.41012
   PubMed Web of Science ®Google Scholar
• Berenbaum F, Blanco FJ, Guermazi A, et al. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann Rheum Dis. 2020;79(6):800–810. doi:10.1136/annrheumdis-2019-216296
   PubMed Web of Science ®Google Scholar
• Schnitzer TJ, Easton R, Pang S, et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA. 2019;322(1):37–48. doi:10.1001/jama.2019.8044
   PubMed Web of Science ®Google Scholar
• Krupka E, Jiang GL, Jan C. Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study. Osteoarthritis Cartilage. 2019;27(11):1599–1607. doi:10.1016/j.joca.2019.05.028
   PubMed Web of Science ®Google Scholar
• Stevens RM, Ervin J, Nezzer J, et al. Randomized, double-blind, placebo-controlled trial of intraarticular trans-capsaicin for pain associated with osteoarthritis of the knee. Arthritis Rheumatol. 2019;71(9):1524–1533. doi:10.1002/art.40894
   PubMed Web of Science ®Google Scholar